• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Sernova Corp. Announces Appointment of New Chief Executive Officer

    8/12/24 7:45:00 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONCY alert in real time by email

    LONDON, Ontario and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- August 12, 2024. Sernova Corp. ("Sernova" or the "Company") (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, led by an ongoing phase 1/2a clinical trial in type 1 diabetes, is pleased to announce Mr. Jonathan Rigby as the Company's new Chief Executive Officer.

    James Parsons, on behalf of the Board of Directors of Sernova, stated, "The Board believes that Sernova is now positioned to achieve its strategic milestones under Jonathan's leadership. Jonathan brings a track record of success raising equity capital for biotech companies. Jonathan has led multiple biotech companies through listings onto Nasdaq, and the achievement of key operational and clinical developments, leading to strategic acquisitions that have generated significant value for shareholders."

    On his appointment, Mr. Rigby commented, "As a type 1 diabetic myself, I am honored to serve the company and its shareholders as Sernova's new CEO. I am passionate about Sernova's mission and determined to lead the Company to realize its full potential. I have financed and grown multiple companies through to exits and my goal is clear; I will work tirelessly with the team to do the same for Sernova and its shareholders."

    Mr. Rigby has held several CEO roles and currently serves on the board of directors of cancer therapy company, Oncolytics Biotech Inc. (NASDAQ:ONCY), and IM Therapeutics, working in the diabetes field. He was formerly a board member of Xeris Pharmaceuticals, which developed and commercialized a product to treat type 1 diabetes severe hypoglycemia. Mr. Rigby holds a degree in biological sciences from the University of Sheffield, U.K., and has a master of business administration degree from the University of Portsmouth, U.K.

    The Board thanks Ms. Cynthia Pussinen, the Company's former CEO, for her dedication and service to the Company and wishes her the very best in her future endeavors.

    ABOUT SERNOVA CORP.

    Sernova Corp. is a clinical-stage biotechnology company that is developing therapeutic cell technologies that are implanted in patients inside its Cell Pouch™ System for chronic diseases, including an ongoing phase 1/2a trial in insulin-dependent diabetes and plans to enter the clinic in thyroid disease, and blood disorders that include hemophilia A. Sernova is currently focused on developing a ‘functional cure' for insulin-dependent diabetes with its lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for long-term survival and function of therapeutic cells that release essential factors that are absent or deficient in the bodies of patients with certain chronic diseases. Sernova's Cell Pouch System has demonstrated its potential to be a ‘functional cure' for people with T1D in an ongoing Phase 1/2 clinical study at the University of Chicago. In May 2022, Sernova and Evotec entered into a global strategic partnership to develop an implantable iPSC (induced pluripotent stem cells) based Cell Pouch islet replacement therapy. This partnership provides Sernova a potentially unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to evaluate the potential for additional development programs that utilize its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex vivo lentiviral Factor VIII gene therapy for hemophilia A.

    FOR FURTHER INFORMATION, PLEASE CONTACT:

    Christopher Barnes

    VP, Investor Relations

    Sernova Corp.

    [email protected]

    519-902-7923

    www.sernova.com

    FORWARD-LOOKING INFORMATION

    This release contains statements that, to the extent they are not recitations of historical facts, may constitute "forward-looking statements" that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management's beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova's actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company's ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company's Cell Pouch System and or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company's quarterly and annual filings available on www.sedarplus.ca for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



    Primary Logo

    Get the next $ONCY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ONCY

    DatePrice TargetRatingAnalyst
    10/6/2022$3.00Buy
    Maxim Group
    More analyst ratings

    $ONCY
    Financials

    Live finance-specific insights

    See more
    • Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

      Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, May 6, 2025 Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Wednesday, May 14, 2025, at 4:30 p.m. ET to discuss a corporate update and financial results for the first quarter of 2025. Conference Call & Webcast Date: Wednesday, May 14, 2025Time: 4:30 p.m. ETDial In – North American Toll-Free: (888) 510-2154Dial In – Interna

      5/6/25 7:00:00 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

      Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, Feb. 25, 2025 /CNW/ --  Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Friday, March 7, 2025, at 8:30 a.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2024. Conference Call & Webcast Date: Friday, March 7, 2025 Time: 8:30 a.m. ETDial In – North American Toll-Free: (888) 510-2154Dial In – International: (437) 900-0527RapidConnect: to join the conference call without operator assistance, plea

      2/25/25 12:43:00 PM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

      Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, Feb. 25, 2025 /PRNewswire/ --  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Friday, March 7, 2025, at 8:30 a.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2024. Conference Call & Webcast Date: Friday, March 7, 2025 Time: 8:30 a.m. ETDial In – North American Toll-Free: (888) 510-2154Dial In – International: (437) 900-0527RapidConnect: to join the conference call without operator assista

      2/25/25 7:00:00 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCY
    SEC Filings

    See more
    • SEC Form 6-K filed by Oncolytics Biotech Inc.

      6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

      5/8/25 5:18:35 PM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Oncolytics Biotech Inc.

      6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

      4/24/25 11:30:14 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Oncolytics Biotech Inc.

      6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

      4/10/25 6:16:03 PM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Oncolytics Biotech with a new price target

      Maxim Group initiated coverage of Oncolytics Biotech with a rating of Buy and set a new price target of $3.00

      10/6/22 9:22:17 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Oncolytics Biotech with a new price target

      H.C. Wainwright initiated coverage of Oncolytics Biotech with a rating of Buy and set a new price target of $15.00

      2/17/21 2:20:07 PM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCY
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ONCY
    Leadership Updates

    Live Leadership Updates

    See more
    • Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

      Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, May 6, 2025 Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Wednesday, May 14, 2025, at 4:30 p.m. ET to discuss a corporate update and financial results for the first quarter of 2025. Conference Call & Webcast Date: Wednesday, May 14, 2025Time: 4:30 p.m. ETDial In – North American Toll-Free: (888) 510-2154Dial In – Interna

      5/6/25 7:00:00 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

      ASCO data expected to highlight how pelareorep activates immune responses in pancreatic cancer patients Ongoing updates support potential of pelareorep combination therapies in one of the deadliest and hardest-to-treat cancers SAN DIEGO and CALGARY, AB, April 24, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will present new data from Cohort 1 of the GOBLET study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago May 30-June 3, 2025 demonstrating pelareorep's anti-tumor activity in pancreatic ductal adenocarcinoma (PDAC) - the most common form of pancreatic ca

      4/24/25 7:00:00 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

      SAN DIEGO and CALGARY, AB, April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, has entered into a share purchase agreement (SPA) with Alumni Capital LP (Alumni), an institutional investor. This partnership will provide Oncolytics with a flexible source of funding, enabling the Company to progress pelareorep toward key clinical milestones and minimize dilution to create and sustain shareholder value. The SPA allows Oncolytics to be judicious and plan for the timing and amount of any equity sales, which will be critical as pelareorep's development continues. Under the terms of the agreeme

      4/10/25 6:09:00 PM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sernova Corp. Announces Appointment of New Chief Executive Officer

      LONDON, Ontario and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- August 12, 2024. Sernova Corp. ("Sernova" or the "Company") (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, led by an ongoing phase 1/2a clinical trial in type 1 diabetes, is pleased to announce Mr. Jonathan Rigby as the Company's new Chief Executive Officer. James Parsons, on behalf of the Board of Directors of Sernova, stated, "The Board believes that Sernova is now positioned to achieve its strategic milestones under Jonathan's leadership. Jonathan brings a track record of success raising equi

      8/12/24 7:45:00 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors

      SAN DIEGO and CALGARY, AB, Jan. 9, 2024 /PRNewswire/ --  Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the appointment of Patricia S. Andrews to its Board of Directors (the "Board"). "I am pleased to welcome Pat Andrews to our Board of Directors," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics. "Pat's extensive board and executive leadership experience navigating first registrational trials in oncology and completing transformational business development agreements with global pharmaceutical companies makes her a natural fit for Oncolytics. As we begin preparations to initiate piv

      1/9/24 7:00:00 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors

      Mr. Rigby is the Group Chief Executive Officer of Revolo Biotherapeutics and has three decades of experience in the pharmaceutical and biotechnology industries SAN DIEGO and CALGARY, AB, Sept. 7, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced the appointment of Jonathan Rigby to its Board of Directors. "Jonathan has successfully built, financed, listed, and led several life science companies across a range of therapeutic areas, and I am thrilled to welcome him to our Board," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc. "His extensive executive leadership experience, together with his business development and co

      9/7/22 7:00:00 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care